prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures

Similar documents
Lessons from recent studies. João Gonçalves Pereira UCIP DALI

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics

ICU Volume 11 - Issue 3 - Autumn Series

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

Disclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past

MRSA Micro Scan Pos Combo 6J DADE BEHRING VCM

Pharmacodynamics: the methods

Teicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients with Neutropenic Fever

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

SCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past

EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING

Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence

PHA Spring First Exam. 8 Aminoglycosides (5 points)

SBUH Aminoglycoside Dosing Protocol

CLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel

VISA infections. Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis

The general Concepts of Pharmacokinetics

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin

Challenges in Therapeutic Drug Monitoring:

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS

Is the package insert correct? PK considerations

Pharmacodynamic indices in targeting therapy of critical infections

D DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.

Treatment of Tuberculosis Therapeutic Drug Monitoring

ESCMID Online Lecture Library. by author

Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics

THERAPEUTIC MONITORING OF VANCOMYCIN IN CLINICAL PRACTICE

Towards clinical Applications of PK-PD in specific situations

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults

Vancomycin Rationale for the EUCAST clinical breakpoints, version June 2010

ภก.วส นต กาต บ. Use of vancomycin is appropriate or acceptable. FDA Labeled Indication

Estimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus

GLYCOPEPTIDES : how can a structural modification bring to a new life an old family of antibiotics?

Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. D. C. Shanson

PK/PD degli antibiotici utilizzati nella sepsi

Pharmacodynamics of sulfamethoxazole in in vitro and in vivo models of tuberculosis

VANCOMYCIN DOSING AND MONITORING GUIDELINES

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Should we be performing TDM in seriously ill patients with Gram negative infections?

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

PHA Final Exam Fall 2006

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

Drug Management in CRRT

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides

Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines

TDM of Aminoglycoside Antibiotics

Evaluation of Vancomycin Continuous Infusion in Trauma Patients

How To Use PK/PD Of Antifungal Drugs In Clinical Practice?

Aminoglycosides John A. Bosso, Pharm.D.

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007

Outline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก

Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2

Long Half-life Drugs in Infectious Diseases: Implications and Complications

(Max 2 g) = to nearest 250 mg

ESCMID Online Lecture Library. by author

ASHP Therapeutic Position Statements 623

Overview. Therapeutic Window. Does drug concentration matter? Treatment of Tuberculosis Therapeutic Drug Monitoring

PHA 5128 Spring 2000 Final Exam

Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first dose: Can we do it with standard dosing?

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

the American Society of Health-System Pharmacists, the Infectious Diseases Society of

The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin

Consequences for the clinicians

Staphylococcal Bacteremia

SCIENTIFIC DISCUSSION

SHC Vancomycin Dosing Guide

Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated

Pediatric Infections: Treatment of Resistant Pathogens. Focus : MRSA and DRSP Infections, Including Pneumonia. Blaise L. Congeni M.D.

Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus

Public Assessment Report Scientific discussion. Vancomycin Farmaplus Vancomycin hydrochloride SE/H/1158/01-02/MR

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006

ESCMID Online Lecture Library. by author

Pharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis

Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

Medication Dosing in CRRT

Vancomycin-associated nephrotoxicity, a case control study

Michael S. Niederman, M.D. Clinical Director Pulmonary and Critical Care Medicine New York Presbyterian Hospital Weill Cornell Medical Center

EMA Workshop Estimating the Probability of Target Attainment

Clinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR GENERAL PRACTICE

Paul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute

NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003

CHMP extension of indication variation assessment report

Pharmacokinetics and safety of Moxifloxacin: Preliminary results of a dose escalation study

Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models

%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.

Spectrum of vancomycin and susceptibility testing

2014 by the Japanese Society for the Study of Xenobiotics (JSSX)

EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Efficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae Strains in a rabbit meningitis model.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Linezolid - Tigecycline

Pharmacokinetics of antibiotics in burn patients. M. J. Weinbren* Microbiology Department, Queen Mary s University Hospital, London, UK

Transcription:

1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam antimicrobials antibiotic-associated colitis (AAC) nonresponding to metronidazole or potentially lifethreatening prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures Comparative efficacy and safety of teicoplanin and vancomycin Wood, JAC 1996) 2 Meta-analysis of 11 clinical trials (1276 pts) Direct comparisons difficult Teicoplanin as effective as vancomycin Teicoplanin superior tolerability (?) Teicoplanin advantages : - once daily, bolus - intramuscular - cost monitoring (cost more but do less!!!) 1

3 Can pharmacokinetics/pharmacodynamics help in optimizing glycopeptide treatments? efficacy (primary end-point) prevention of emergence of resistance (secondary but crucial endpoint) 4 Glycopeptides PK/PD: which is the important parameter? slowly cidal time-dependent killing long half-life AUC/MICratio But, what is this? 2

5 Area under the curve (AUC) dependent on the total dose and half-life 6 AUC / MIC ratio dependent on the total dose, half-life and MIC 3

7 AUC vs peak and trough In a given schedule, peak and trough levels, and AUC are directly correlated to one another to the dose to the inverse of the clearance 8 Peak, trough, and AUC are interelated... Vancomycin serum concentration 30 10 3 1 30 15 7.5 1g 0.5g 0.25 g An example with vancomycin... AUC= 200 AUC= 100 AUC= 50 8 4 2 0 Time (hours) 12 4

9 Glycopeptides dosing recommendations at the Cliniques Saint-Luc Vancomycin start with 1 g / 12 h and then: peak (t 0 ) 25-35 mg/l trough 5-10 mg/l AUC 200 mg/l x h -1 AUC 24h 400 mg/l x h -1 10 Vancomycin Outcomes vs MIC and AUC/MICs MIC >1.0 µg/ml 1 4 a 0 MIC <1.0 µg/ml 74 2 3 AUC / MIC <125 4 4 b 0 AUC / MIC >125 71 2 3 Total Patients (84) 75 6 3 a p < 0.001 b p < 0.005 Outcome Satisfactory Unsatisfactory Indeterminate Hyatt, et al. Clin Pharmacokinet. 1995;28:143-160. 5

11 Vancomycin 1g every 12h (normal adult) PK/PD parameters for 1g every 12h MIC Peak/MIC 24h-AUC/MIC 1 30 400 2 15 200 4 7.5 100 8 3.75 50 Vancomycin time to eradication in MRSA Infections 12 Percent Culture Positive 100 80 60 40 20 24h-AUC/MIC <400 (n=16) P=0.0402 24h-AUC/MIC >400 (n=18) 0 0 10 20 30 Day of Eradication Moise, Forrest & Schentag. Submitted, 2000. 6

Vancomycin /Teicoplanin PK/PD parameters taking into account protein binding 13 protein half 24h-AUC * MIC binding life total free ** max * (%) (h) mg/l xh -1 mg/l vancomycin 10-50 % 6 400 200 1-2 (1g / 12h) teicoplanin 90 > 40 560 56 0.5 (6 mg/kg in 24h) * values directly proportional to the dose ** in vitro and animal PK/PD studies of most antibiotics show that only free drug is active 14 Teicoplanin recommanded levels common indications : trough > 10 mg/l 6 mg / (kg x d) for S. aureus septicemia, S. aureus endocarditis, osteoarthritis, trough > 20 mg/l 12 mg / (kg x d) if every other day 18 mg / kg every 48 h 7

15 Conclusions (1/3)... Both vancomycin and teicoplanin should be used restrictively!! If needed, both should be administered correctly Monitoring is beneficial if associated with a full PK analysis avoidance/correction in errors of administration decreased incidence of side effects increased efficacy We need MIC s... True monitoring is never a single determination!! 8